Skip to content

Denali Therapeutics

US · DNLI #2454 by market cap Listed 2017
18.45 +0.25 +1.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 9 in the most recent period (2026/Q3).
  • Total institutional ownership fell 5.4 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
99.11% -5.40pp
Institutions
348 -9
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund74.88%
Hedge Fund10.18%
VC/PE Fund7.80%
Individual/Insider2.96%
Public Company2.87%
Sovereign Wealth Fund1.77%
Private Company0.55%
Government Pension Fund0.52%
Endowment Fund0.29%
Insurance Company0.20%

Top holders as of 2026-06-30

T. Rowe Price Group, Inc. 12.05% · 19.32M sh
BlackRock 8.94% · 14.33M sh
Baillie Gifford 6.94% · 11.12M sh
Temasek Holdings 4.38% · 7.01M sh
Vanguard Portfolio Management, LLC 4.22% · 6.76M sh
Vanguard Capital Management, LLC 4.21% · 6.75M sh
State Street Global Advisors 4.17% · 6.68M sh
UBS Asset Management 3.53% · 5.67M sh
FMR 2.82% · 4.52M sh
Geode Capital Management, LLC 2.52% · 4.04M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 31 buys · 17 sells

NameRoleStake
Ryan Watts Chief Executive Officer 1.39%
Steve Krognes Independent Director 0.51%
Alexander Schuth Co-Founder, CFO, COO & Secretary 0.42%
Jay Flatley Independent Director 0.22%
Julian Baker Independent Chairperson 0.21%
Peter Chin Acting Chief Medical Officer & Head of Development 0.13%
David Schenkein Independent Director 0.05%
Peter Klein Independent Director 0.02%
Jennifer Cook Independent Director 0.02%
Nancy Thornberry Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-03 Peter Chin Acting Chief Medical Officer & Head of Development Open Market Disposition -1,654 $22.29
2026-09-01 Nancy Thornberry Independent Director Automatic Disposition -11,439 $22.85–23.74
2026-08-31 Alexander Schuth Co-Founder, CFO, COO & Secretary Automatic Disposition -2,768 $23.44
2026-08-11 Ryan Watts Chief Executive Officer Other Disposition -32,220 --
2026-08-10 Alexander Schuth Co-Founder, CFO, COO & Secretary Open Market Disposition -2,857 $25.07
2026-06-02 Jay Flatley Independent Director Other Acquisition +6,408 --
2026-06-02 Jay Flatley Independent Director Other Derivative Acquisition +19,226 $19.66
2026-06-02 Julian Baker Independent Chairperson Other Acquisition +12,816 --
2026-06-02 Julian Baker Independent Chairperson Other Derivative Acquisition +19,226 $19.66
2026-06-02 David Schenkein Independent Director Other Acquisition +6,408 --
2026-06-02 David Schenkein Independent Director Other Derivative Acquisition +19,226 $19.66
2026-06-02 Peter Klein Independent Director Other Acquisition +6,408 --
2026-06-02 Peter Klein Independent Director Other Derivative Acquisition +19,226 $19.66
2026-06-02 Jennifer Cook Independent Director Other Acquisition +6,408 --
2026-06-02 Jennifer Cook Independent Director Other Derivative Acquisition +19,226 $19.66
2026-06-02 Timothy Van Hauwermeiren -- Other Acquisition +6,408 --
2026-06-02 Timothy Van Hauwermeiren -- Other Derivative Acquisition +19,226 $19.66
2026-06-02 Steve Krognes Independent Director Other Acquisition +6,408 --
2026-06-02 Steve Krognes Independent Director Other Derivative Acquisition +19,226 $19.66
2026-06-02 Nancy Thornberry Independent Director Other Acquisition +6,408 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Denali Therapeutics discussion 0 comments

Add a comment